Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filtering shows promise for severe COVID-19 patients

NCT ID NCT04751643

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether filtering the blood (therapeutic plasma exchange) could help severe COVID-19 patients by removing harmful immune molecules that cause lung damage. Twenty-one adults in intensive care with COVID-19 and lung failure were randomly assigned to receive either blood filtering plus standard care or standard care alone. The main goal was to see if the treatment reduced the need for a breathing tube.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
therapeutic plasma exchange (blood filtering)
What this could lead to
If it works, this could provide a way to quickly calm the immune overreaction in severe COVID-19, potentially reducing the need for breathing machines.
What could go wrong
This was a very small, early trial with only 21 participants, so results may not apply broadly. Plasma exchange also carries risks like allergic reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

21 people

The number who actually took part.

Started

Apr 2021

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Hospitalized for COVID-19 confirmed by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) or scanner * Patients with PaO2/FiO2 between 75 and 175 mmHg requiring non invasive ventilation or high flow oxygen * peripheral venous state allowing PE to be performed, according to the investigator's judgement, or possibility of placing a Sheldon-type veinous central line * At least two biological results suggesting a cytokine storm or hyperinflammatory condition state among : C-reactive protéine (CRP)\>50mg/L, Procalcitonin (PCT)\>1µg/L, Fibrinogen\>5g/L, D-dimer \>1000ng/mL, Ferritin \> 800ng/mL during the last 72 hours. * Treatment with corticosteroids (at least 2 intakes of dexamethasone 6 mg or equivalent with another form of corticosteroids) * Patient affiliated to a social security or similar scheme * Information and written consent from the patient or if not possible from a confident person Exclusion Criteria: * Ventilated intubated patients * Patient with advanced cancer and without curative possibility * Bacterial or viral (HIV) infection explaining the worsening (the main reason) * Body Mass Index \> 40 * Severe hemodynamic instability with mean arterial pressure \< 65 mmHg (whatever the noradrenaline dosage used) * Known Immunoglobulin A (IgA) deficiency with anti-IgA antibodies * Inclusion in another study that could interact with the Covidep study (investigator's judgement) * Patient under legal protection measure * Pregnant or breastfeeding women * In case of allergy to amotosalen (psoralens) or AI-FFP (Amotosalen Inactivated Fresh Frozen Plasma) , use Se-FFP (Secured Fresh Frozen Plasma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, human are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19 cytokine release syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS, human COVID19 Intensive care units

Contacts and locations

Locations

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, 71100, France

  • Clinique de la Sauvegarde

    Lyon, 69337, France

  • Groupement Hospitalier Porte de Valence - Montélimar

    Montélimar, 26216, France

  • Hôpital Croix Rousse

    Lyon, 69004, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

  • Hôpital Pitié Salpétrière - Assistante Publique des Hôpitaux de Paris

    Paris, 75013, France

  • Medipole Villeurbanne

    Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.